Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Consolidated Net Income: 2021-2024

Historic Consolidated Net Income for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Consolidated Net Income fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Consolidated Net Income stood at $8.0 million, which was up 114.71% from -$54.4 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Consolidated Net Income registered a high of $8.0 million during FY2024, and its lowest value of -$54.4 million during FY2023.
  • Moreover, its 3-year median value for Consolidated Net Income was -$35.5 million (2022), whereas its average is -$27.3 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 82.56% in 2022, then spiked by 114.71% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Consolidated Net Income (Yearly) stood at -$19.5 million in 2021, then crashed by 82.56% to -$35.5 million in 2022, then tumbled by 53.07% to -$54.4 million in 2023, then soared by 114.71% to $8.0 million in 2024.